Distribution analysis of WBC and sputum NSP activities
The WILLOW trial randomized 256 patients, and 89, 81 and 85 had sputum NSP activity data in the 25 mg brensocatib, 10 mg brensocatib, and placebo groups, respectively. Baseline and post-baseline NE activity data in blood was reportable for 37, 30 and 35 patients, respectively. The prespecified analysis of sputum NSP activities assumed that they followed a lognormal distribution profile. This assumption was confirmed for NE, PR3 and CatG. The WBC NE activity followed a normal distribution profile. These analyses are shown in Additional file 